Ocrevus (Ocrelizumab)

Ocrelizumab, the active ingredient in Ocrevus, is a monoclonal antibody presented as a solution for injection for subcutaneous use. It selectively depletes CD20‑positive B cells and is indicated for the treatment of multiple sclerosis, including relapsing‑remitting forms and primary progressive disease, in adult patients. The therapy is administered under medical supervision and requires periodic monitoring of immune status.

GNH USA supplies Ocrevus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Ocrevus is a disease‑modifying therapy that targets B‑cell activity in multiple sclerosis.

- Relapsing‑remitting multiple sclerosis: reduces relapse frequency and slows disability progression. - Primary progressive multiple sclerosis: slows accumulation of disability in adults. - Active disease in adults: decreases MRI lesion activity and inflammatory activity.

Common Side Effects: - Infusion‑related reactions: flushing, rash, or shortness of breath during or shortly after administration. - Infections: upper respiratory tract infections, sinusitis, or urinary tract infections. - Fatigue, headache, or nausea.

Serious or Rare Side Effects: - Opportunistic infections including reactivation of hepatitis B. - Progressive multifocal leukoencephalopathy (PML). - Severe infusion reactions such as anaphylaxis. - Cardiac events including arrhythmias. - Malignancies reported in long‑term use. - Hepatic injury with elevated liver enzymes.

Before initiating therapy, patients should be evaluated for infection risk and vaccination status.

- Screen for active infections: assess and treat before first dose. - Monitor immunoglobulin levels: periodic blood tests to detect hypogammaglobulinemia. - Vaccination: administer required vaccines, especially non‑live, prior to treatment. - Pregnancy and breastfeeding: avoid unless benefits outweigh potential risks. - Concomitant immunosuppressants: use with caution and close monitoring. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ocrevus may interact with other agents that affect immune function.

Major Interactions (Avoid): - Live vaccines: contraindicated during and for several weeks after treatment. - Concurrent B‑cell depleting agents: increased risk of profound immunosuppression. - Severe hypersensitivity to ocrelizumab: avoid further exposure.

Moderate Interactions (Monitor Closely): - Antiviral prophylaxis (e.g., for hepatitis B): monitor viral load and liver function. - Immunosuppressive chemotherapy: adjust monitoring frequency and infection surveillance. - Non‑live vaccines: efficacy may be reduced; assess antibody response. - Other immunomodulators: consider cumulative immunosuppressive effect.